Wockhardt Limited (WOCKPHARMA) AI Stock Analysis

• Market Cap: ₹221.79B
• Dividend Yield: N/A
• Average Volume (3M): 42.24K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.79
• Revenue Growth: 4.08%
• EPS Growth: 67.87%
• Country: IN
• Employees: 2,386
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 4.80
• Shares Outstanding: 162,485,570
• 10 Day Avg. Volume: 36,933
• 30 Day Avg. Volume: 42,239
• PEG Ratio: 5.24
• Price to Book (P/B): 5.12
• Price to Sales (P/S): 7.40
• P/FCF Ratio: -84.38
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: ₹1,401.00 ▲(4.20% Upside)

Wockhardt Limited's overall stock score reflects significant financial challenges, with persistent net losses and negative cash flows being the most impactful factors. Technical analysis provides mixed signals, while valuation concerns due to a negative P/E ratio further weigh down the score. The absence of earnings call and corporate events data limits additional insights.

Wockhardt Limited Business Overview & Revenue Model

Company Description

Wockhardt Limited (WOCKPHARMA) is a global pharmaceutical and biotechnology company headquartered in Mumbai, India. Established in 1960, Wockhardt focuses on the research, development, manufacturing, and marketing of a range of pharmaceuticals, including generic medications, biosimilars, and vaccines. The company operates in various therapeutic areas such as diabetes, cardiovascular diseases, and anti-infectives, and has a significant presence in both emerging and developed markets. Wockhardt also emphasizes advanced drug delivery systems and has a strong pipeline of products in development.

How the Company Makes Money

Wockhardt Limited generates revenue primarily through the sale of its pharmaceutical products, which include branded and generic drugs, biosimilars, and vaccines. The company's revenue model is diversified across multiple segments, including domestic sales in India and exports to various international markets. Key revenue streams include sales from its core therapeutic areas, particularly in the pharmaceutical and biotechnology sectors. Additionally, Wockhardt benefits from strategic partnerships and collaborations with other pharmaceutical companies, which enhance its research capabilities and market reach. The company also engages in contract manufacturing, providing services to other pharmaceutical firms, which contributes to its overall earnings. Factors such as a strong product pipeline, regulatory approvals for new drugs, and expansion into new markets further bolster its revenue-generating potential.

Wockhardt Limited Financial Statement Overview

Summary

Wockhardt Limited faces significant financial challenges, with negative profitability and cash flow metrics. Despite improvements in revenue and gross profit margins, persistent net losses and negative cash flows pose ongoing risks. The balance sheet is stable with improving leverage ratios, but profitability needs addressing.

Income Statement

Wockhardt Limited's income statement reflects a challenging financial position. Despite a positive revenue growth of 8.01% in the most recent year, the company has consistently recorded net losses over the past few years, reflected in a negative net profit margin. However, the company has managed to improve its gross profit margin to 33.59% in 2025 from 27.68% in 2024, indicating some operational improvements. Both EBIT and EBITDA margins remain weak, though they show improvement from previous years.

Balance Sheet

The balance sheet of Wockhardt Limited presents a mixed picture. The debt-to-equity ratio has improved to 0.46 in 2025 from 0.70 in 2024, reflecting reduced leverage. The company's equity ratio stands at 53.51%, which indicates a stable capital structure. However, the company has faced declining stockholders' equity in previous years, which poses a risk if not managed effectively. Return on equity remains negative due to persistent net losses.

Cash Flow

Wockhardt Limited's cash flow statement highlights significant cash flow challenges. The operating cash flow has turned negative in the latest year, primarily due to net losses. Free cash flow is also negative, reflecting capital expenditure and investment needs not being met by cash generation from operations. The company has shown a volatile free cash flow growth rate, indicating fluctuating operational efficiency.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	30.34B	30.35B	28.30B	26.57B	32.30B	27.08B
Gross Profit	18.74B	18.26B	15.98B	14.85B	18.81B	14.98B
EBITDA	3.83B	3.60B	1.38B	420.00M	2.26B	-1.43B
Net Income	-1.23B	-470.00M	-4.63B	-5.59B	-2.44B	6.86B
Balance Sheet
Total Assets	0.00	81.35B	76.49B	76.83B	82.43B	77.73B
Cash, Cash Equivalents and Short-Term Investments	5.88B	6.13B	5.23B	1.50B	3.79B	2.38B
Total Debt	0.00	20.21B	23.56B	21.84B	21.98B	26.73B
Total Liabilities	-46.57B	34.78B	39.87B	40.21B	40.41B	40.12B
Stockholders Equity	46.57B	43.53B	33.59B	33.54B	38.49B	33.77B
Cash Flow
Free Cash Flow	0.00	-2.64B	30.00M	-560.00M	2.01B	-4.53B
Operating Cash Flow	0.00	-220.00M	2.19B	1.53B	4.13B	-2.87B
Investing Cash Flow	0.00	-7.83B	-1.37B	-1.25B	-2.01B	14.70B
Financing Cash Flow	0.00	4.09B	3.34B	-3.15B	-710.00M	-11.71B

Wockhardt Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1344.55
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:WOCKPHARMA, the sentiment is Neutral. The current price of 1344.55 is below the 20-day moving average (MA) of 1355.19, below the 50-day MA of 1430.95, and below the 200-day MA of 1461.98, indicating a neutral trend. The MACD of -31.78 indicates Negative momentum. The RSI at 48.32 is Neutral, neither overbought nor oversold. The STOCH value of 49.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:WOCKPHARMA.

Wockhardt Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AUROPHARMA	78 Outperform	₹668.50B	19.71	―	0.35%	7.76%	-2.84%
DRREDDY	73 Outperform	₹1.00T	17.09	―	0.66%	14.10%	9.72%
ALKEM	72 Outperform	₹677.34B	29.65	―	0.79%	4.49%	11.22%
IPCALAB	60 Neutral	₹328.58B	42.21	―	0.31%	11.49%	35.00%
GLENMARK	53 Neutral	₹521.13B	69.14	―	0.14%	10.99%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
WOCKPHARMA	48 Neutral	₹221.79B	―	―	―	4.08%	67.87%

Wockhardt Limited Corporate Events

Wockhardt Submits NDA for Novel Antibiotic to U.S. FDA

Wockhardt Limited has submitted a New Drug Application to the U.S. FDA for Zidebactam-Cefepime (WCK 5222), a novel antibacterial agent designed to treat serious Gram-negative infections, including complicated urinary tract infections. This submission is a significant milestone as it represents the first-ever NDA submission by an Indian pharmaceutical company for a drug fully discovered and developed in India. The drug, which has shown efficacy against multi-drug resistant pathogens, has been granted qualified infectious disease product and Fast Track Designation by the US FDA, highlighting its potential impact on addressing antimicrobial resistance globally.

Wockhardt Limited Reports Q1 2025 Financial Results

Wockhardt Limited announced the approval of its unaudited financial results for the quarter ending June 30, 2025, by its Board of Directors. The results, which include both standalone and consolidated figures, were reviewed by the company’s statutory auditors, MSKC & Associates, and found to comply with Indian Accounting Standards and regulatory requirements. This announcement is a routine disclosure in compliance with SEBI regulations, and it reflects the company’s ongoing commitment to transparency and regulatory adherence.